Summary

The hepatitis C testing market was valued at $1.5 billion in 2023 and is estimated to reach $2.6 billion by 2035, exhibiting a CAGR of 4.9% from 2024 to 2035. Hepatitis C is a viral infection caused by the hepatitis C virus (HCV), primarily targeting the liver and posing a significant risk of progressing to chronic liver disease, cirrhosis, and liver cancer if left untreated. The virus spreads primarily through blood-to-blood contact, commonly occurring due to the sharing of contaminated needles, unsterilized medical equipment, or blood transfusions performed before the widespread implementation of rigorous screening protocols. Given the severe health implications of hepatitis C, early and accurate diagnosis is critical in managing the disease effectively. The diagnostic process for hepatitis C typically begins with antibody tests, which help detect prior exposure to the virus. If the initial antibody test yields a positive result, confirmatory testing is performed using RNA-based assays to determine the presence and concentration of the virus in the bloodstream. Advanced molecular techniques, such as polymerase chain reaction (PCR), play a vital role in confirming an active infection and evaluating the viral load, which is essential for treatment planning and monitoring disease progression.
The prevalence of hepatitis C cases globally has amplified the need for reliable and efficient diagnostic solutions. Hepatitis C remains a major public health challenge, as millions of individuals worldwide suffer from either undiagnosed or untreated infections, thus driving the necessity for advanced diagnostic tools capable of facilitating early detection, enabling prompt medical intervention and improving patient outcomes. Furthermore, technological advancements in molecular diagnostics have significantly enhanced the accuracy, efficiency, and speed of hepatitis C testing, making it possible to detect even minimal traces of the virus in a patient’s blood. These innovations have paved the way for early diagnosis, which is crucial in preventing the disease from progressing to severe liver complications.
A major breakthrough in hepatitis C diagnostics is the introduction of multiplex diagnostic kits, which allow simultaneous detection of multiple infections in a single test. This advancement has proven to be highly beneficial in improving diagnostic efficiency while reducing testing costs and turnaround time. One notable example is Trivitron Healthcare’s Triple H (HIV/HCV/HBV) Multiplex Real-Time PCR Kit, an innovative molecular diagnostic tool designed to detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) within a single testing process. The integration of such cutting-edge technology streamlines the diagnostic workflow, minimizing the need for multiple tests and expediting the initiation of treatment. The availability of these advanced diagnostic solutions has improved the accessibility and reliability of hepatitis C testing, ensuring more individuals receive timely and accurate diagnoses.
Another factor contributing to the rise in demand for hepatitis C testing is the increase in number of blood donations. Blood transfusions are an essential medical procedure worldwide, playing a crucial role in saving lives in various medical emergencies. Since hepatitis C is a bloodborne virus, ensuring the safety of donated blood is a top priority for healthcare institutions and regulatory bodies. Rigorous screening measures have been implemented to prevent transmission through blood transfusions, further driving the need for high-precision diagnostic methods. As voluntary blood donation programs continue to gain traction, hospitals and blood banks are increasingly adopting sophisticated testing methodologies to uphold stringent blood safety standards. Thus, the rising hepatitis C cases, continuous advancements in diagnostic technologies, and the adoption of multiplex testing solutions are expected to propel the growth of the hepatitis C testing market. With rise in focus on early detection of hepatitis C disease, infection control, and public health initiatives, the integration of molecular diagnostic tools is expected to continue to enhance disease surveillance and management. The development of innovative diagnostic platforms is projected to be instrumental in strengthening global efforts to control the spread of hepatitis C, ultimately contributing to improved healthcare outcomes and reducing the burden of the disease.
The hepatitis C testing market is segmented into technique, test, end user, and region. On the basis of technique, it is segregated into immunoassay, polymerase chain reaction (PCR), and others. The polymerase chain reaction (PCR) segment is further classified into real time PCR, and other PCR. On the basis of test, it is classified into antibody test, genotype tests, and viral load test. On the basis of end user, it is divided into hospital & diagnostic laboratory, blood banks, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The major companies profiled in the report include Abbott Laboratories, Cosara Diagnostics Pvt Ltd, Meril Life Sciences Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., Qiagen N.V., Trivitron Healthcare, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., and Thermo Fisher Scientific Inc. The key players have adopted product approval, partnership, and product launch as the key strategies for expansion of their product portfolio.
Key Benefits for Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2023 to 2035 to identify the prevailing hepatitis c testing market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the hepatitis c testing market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● New Product Development/ Product Matrix of Key Players
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technique
● Immunoassay
● PCR
○ Type
○ Real time PCR
○ Other PCR
● Other Techniques
By Test
● Antibody test
● Genotype tests
● Viral load test
By End User
● Hospital and Diagnostic Laboratory
● Blood Banks
● Other End Users
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Bio-Rad Laboratories, Inc. 
○ F. Hoffmann-La Roche Ltd.
○ Thermo Fisher Scientific Inc.
○ Qiagen N.V.
○ Abbott Laboratories
○ Cosara Diagnostics Pvt Ltd
○ Hologic, Inc.
○ Molbio Diagnostics Pvt. Ltd.
○ Meril Life Sciences Pvt. Ltd.
○ Trivitron Healthcare

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Presence of prevalence of hepatitis C cases
3.4.1.2. Availability of standard guidelines
3.4.1.3. Growing adoption of point of care testing
3.4.2. Restraints
3.4.2.1. Regulatory challenges and low awareness
3.4.3. Opportunities
3.4.3.1. Technological advancements in hepatitis C testing
CHAPTER 4: HEPATITIS C TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immunoassay
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. PCR
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. PCR Hepatitis C Testing Market by Type
4.3.4.1. Real time PCR Market size and forecast, by region
4.3.4.2. Other PCR Market size and forecast, by region
4.4. Other Techniques
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: HEPATITIS C TESTING MARKET, BY TEST
5.1. Overview
5.1.1. Market size and forecast
5.2. Antibody test
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Genotype tests
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Viral load test
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: HEPATITIS C TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital and Diagnostic Laboratory
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Blood Banks
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Other End Users
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: HEPATITIS C TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Technique
7.2.2.1. North America PCR Hepatitis C Testing Market by Type
7.2.3. Market size and forecast, by Test
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Technique
7.2.5.1.2. Market size and forecast, by Test
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Technique
7.2.5.2.2. Market size and forecast, by Test
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Technique
7.2.5.3.2. Market size and forecast, by Test
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Technique
7.3.2.1. Europe PCR Hepatitis C Testing Market by Type
7.3.3. Market size and forecast, by Test
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Technique
7.3.5.1.2. Market size and forecast, by Test
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Technique
7.3.5.2.2. Market size and forecast, by Test
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Technique
7.3.5.3.2. Market size and forecast, by Test
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Technique
7.3.5.4.2. Market size and forecast, by Test
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Technique
7.3.5.5.2. Market size and forecast, by Test
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Technique
7.3.5.6.2. Market size and forecast, by Test
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Technique
7.4.2.1. Asia-Pacific PCR Hepatitis C Testing Market by Type
7.4.3. Market size and forecast, by Test
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Technique
7.4.5.1.2. Market size and forecast, by Test
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Technique
7.4.5.2.2. Market size and forecast, by Test
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Technique
7.4.5.3.2. Market size and forecast, by Test
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Technique
7.4.5.4.2. Market size and forecast, by Test
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Technique
7.4.5.5.2. Market size and forecast, by Test
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Technique
7.4.5.6.2. Market size and forecast, by Test
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Technique
7.5.2.1. LAMEA PCR Hepatitis C Testing Market by Type
7.5.3. Market size and forecast, by Test
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Technique
7.5.5.1.2. Market size and forecast, by Test
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Technique
7.5.5.2.2. Market size and forecast, by Test
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Technique
7.5.5.3.2. Market size and forecast, by Test
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Technique
7.5.5.4.2. Market size and forecast, by Test
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Cosara Diagnostics Pvt Ltd
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. Meril Life Sciences Pvt. Ltd.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Molbio Diagnostics Pvt. Ltd.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Qiagen N.V.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Trivitron Healthcare
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Bio-Rad Laboratories, Inc. 
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Hologic, Inc.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Thermo Fisher Scientific Inc.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance